EVIMay 30, 2022ShigETEC vaccine candidate against diarrhoeal disease proved to be safe in phase I clinical trialDiarrhoea is one of the most common diseases, globally, affecting children under five years of age. Although typically being a...
EVISep 24, 2020Eveliqure announces the start of a Phase 1 clinical study of its combined Shigella and ETEC vaccineShigETEC is an orally administered vaccine candidate developed by Eveliqure.
EVINov 5, 2019Eveliqure's effort to develop a Shigella-ETEC combination vaccine is supported by the Wellcome TrustShigella-ETEC combination vaccine for travellers and children in resource poor countries is supported by the Wellcome Trust.
EVIOct 25, 2019“Success Story” series of the Austrian Research Promotion Agency (FFG) The SHIGETECVAX consortium and Eveliqure included in the “Success Story” series of the Austrian Research Promotion Agency (FFG)